Evotec Expands its 2016 Agreement with Bristol-Myers Squibb
Shots:
- Evotec to receive $6M payment from BMS to expand its partnership with the inclusion of additional cell lines
- In 2016- Evotec signed a 5-year research agreement with Celgene (now a part of BMS) for the identification of therapies based on Evotec’s technology platforms in conjunction with the human iPSC- based platform for multiple neurodegenerative diseases
- iPSCs are adult cells genetically reprogrammed to an embryonic stem cell for expressing genes & properties of embryonic stem cells
Click here to read full press release/ article | Ref: Evotec | Image: Behance
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com